Learning Objectives: Have increased knowledge regarding the Clinical trial evidence for tyrosine kinase inhibitors (TKIs) therapies in CML Have greater competence related to Selecting TKI therapies across the CML treatment continuum Managing TKI therapies in patients with CML Demonstrate greater confidence in their ability to Personalize treatment with TKI therapies in CML to optimize responses
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://www.medscape.org/viewarticle/1001658
- Start Date: 2024-09-30 05:00:00
- End Date: 2024-09-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Enliven - Amount: 8000.0 - Is Kind Support: False Source: Novartis - Amount: 91000.0 - Is Kind Support: False Source: Takeda Pharmaceuticals (Any division) - Amount: 41000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest